SCHEMBL396700

SCHEMBL396700

Nc1ccc(S(=O)(=O)N2CCCCC2c2cccnc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 1.00
USP2 O75604 1/20 1.00
CYP3A4 P08684 1/20 0.80
CYP2C19 P33261 1/20 0.80
ADRB2 P07550 3/20 0.69
TSHR P16473 1/20 0.69
MAPT P10636 5/20 0.62
MAPK1 P28482 2/20 0.62
HTT P42858 2/20 0.62
LMNA P02545 2/20 0.62
TP53 P04637 1/20 0.62
POLB P06746 3/20 0.61
KMT2A Q03164 2/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
KDM4E B2RXH2 2/20 0.58
PSEN1 P49768 1/20 0.56
PSEN2 P49810 1/20 0.56
APH1B Q8WW43 1/20 0.56
NCSTN Q92542 1/20 0.56
APH1A Q96BI3 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5307006 0.88 CYP3A4 (0.80) ALDH1A1USP2CYP3A4CYP2C19ADRB2
SCHEMBL5717083 0.86 CYP3A4 (0.77) ALDH1A1USP2CYP3A4CYP2C19ADRB2
SCHEMBL6178010 0.84 CYP3A4 (0.74) ALDH1A1USP2CYP3A4CYP2C19ADRB2
SCHEMBL1645112 0.82 CYP3A4 (0.70) ALDH1A1USP2CYP3A4CYP2C19ADRB2
SCHEMBL397940 0.82 ALDH1A1 (1.00) ALDH1A1USP2CYP3A4CYP2C19ADRB2
SCHEMBL13036465 0.81 CYP3A4 (0.68) ALDH1A1USP2CYP3A4CYP2C19ADRB2
SCHEMBL11959680 0.81 CYP3A4 (0.68) ALDH1A1USP2CYP3A4CYP2C19ADRB2
SCHEMBL11559696 0.79 CYP3A4 (0.66) ALDH1A1USP2CYP3A4CYP2C19ADRB2
SCHEMBL24015601 0.77 CYP3A4 (0.66) ALDH1A1USP2CYP3A4CYP2C19ADRB2
SCHEMBL24016026 0.77 CYP3A4 (0.66) ALDH1A1USP2CYP3A4CYP2C19ADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101580-B2 Therapeutic agent for irritable bowel syndrome ASTELLAS PHARMA INC. (JP) 2012-01-24 US disclosed
US-20090093415-A1 THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME ASTELLAS PHARMA INC. (JP) 2009-04-09 US disclosed
EP-1872795-A1 THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME Astellas Pharma Inc. (JP) 2008-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093415-A1 THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME BRS3, VIPR2, BDKRB2 ALDH1A1 4743/4885USP2 760/4885CYP3A4 4298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.